Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2346-2357

  Dudley, Mark E ^a   Wunderlich, John R ^a   Yang, James C ^a   Sherry, Richard M ^a   Topalian, Suzanne L ^a   Restifo, Nicholas P ^a   Royal, Richard E ^a   Kammula, Udai ^a   White, Don E ^a   Mavroukakis, Sharon A ^a   Rogers, Linda J ^a   Gracia, Gerald J ^a   Jones, Stephanie A ^a   Mangiameli, David P ^a   Pelletier, Michelle M ^a   Gea Banacloche, Juan ^a   Robinson, Michael R ^a   Berman, David M ^a   Filie, Armando C ^a   Abati, Andrea ^a   Rosenberg, Steven A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CELL THERAPY; CEREBRAL BLINDNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DYSPNEA; ERYTHROCYTE COUNT; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NEUTROPHIL COUNT; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REFRACTORY PERIOD; SIDE EFFECT; SKIN METASTASIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEITIS; VIRUS INFECTION; VITILIGO; ADOPTIVE TRANSFER; CHILD; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; SKIN TUMOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TREATMENT OUTCOME; VIDARABINE;

EID: 20244366111     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.240     Document Type: Article

References (33)

1. Dudley ME, Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675, 2003
2. Eberlein TJ, Rosenstein M, Rosenberg SA: Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 156:385-397, 1982
3. Overwijk WW, Tsung A, Irvine KR, et al: gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277-286, 1998
4. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
5. Cheever MA, Greenberg PD, Fefer A: Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 125: 711-714, 1980
6. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063-1074, 1982
7. Klebanoff CA, Finkelstein SE, Surman DR, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101:1969-1974, 2004
8. Overwijk WW, Theoret MR, Finkelstein SE, et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-580, 2003
9. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
10. Yannelli JR, Hyatt C, McConnell S, et al: Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 65:413-421, 1996
11. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
12. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000
13. Dudley ME, Wunderlich JR, Yang JC, et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243-251, 2002
14. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11-S14, 2000 (suppl 1)
15. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
16. Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352, 1994
17. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995
18. Dudley ME, Wunderlich J, Nishimura MI, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373, 2001
19. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201, 1990
20. Fetsch PA, Marincola FM, Filie A, et al: Melanoma-associated antigen recognized by T cells (MART-1): The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer 87:37-42, 1999
21. Cormier JN, Hijazi YM, Abati A, et al: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517-524, 1998
22. Huang J, el Gamil M, Dudley ME, et al: T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 172:6057-6064, 2004
23. Gratwohl A, Brand R, Apperley J, et al: Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 100:3877-3886, 2002
24. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
25. Overwijk WW, Lee DS, Surman DR, et al: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 96:2982-2987, 1999
26. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
27. + T dells and fails in the presence of naturally occurring T regulatory cells. J Immunol 174:2591-2601, 2005
28. Ma J, Urba WJ, Si L, et al: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33:2123-2132, 2003
29. Mackall CL, Gress RE: Thymic aging and T-cell regeneration. Immunol Rev 160:91-102, 1997
30. Rutella S, Pierelli L, Bonanno G, et al: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 100:2562-2571, 2002
31. Sloand EM, Kim S, Maciejewski JP, et al: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95:2269-2274, 2000
32. Rosenberg SA, Yang JC, Robbins PF, et al: Cell transfer therapy for cancer: Lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26:385-393, 2003
33. Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168-16173, 2002